Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Zytiga, Abirapro, Yonsa
Abiraterone acetate is a medication used in the treatment of prostate cancer. It's classified as an antiandrogen, specifically an inhibitor of CYP17A1, an enzyme crucial for androgen biosynthesis. By blocking this enzyme, abiraterone reduces androgen production in the testes, adrenal glands, and even the tumor itself. This is particularly important in managing prostate cancer, a hormone-sensitive cancer that relies on androgens for growth and survival. Abiraterone is typically administered with prednisone to mitigate potential side effects related to mineralocorticoid excess.
For the treatment of metastatic castration-resistant prostate cancer.
Outcome:
Reduced abiraterone efficacy
Mechanism:
Increased abiraterone metabolism
Outcome:
Potential for increased calcium channel blocker concentrations
Mechanism:
CYP3A4 inhibition
Outcome:
Generally safe to co-administer
Mechanism:
Minimal interaction expected
Most likely new formulation: Combination therapies incorporating abiraterone with other targeted agents (2025, 70% confidence)
Based on current clinical trial data and post-market surveillance, abiraterone is likely to maintain its current approval status for the treatment of prostate cancer.
Antineoplastic Agent, Antiandrogen, CYP17A1 Inhibitor
Steroid